Innovative Therapeutics Focus 858 Therapeutics specializes in developing small molecule drugs targeting novel mechanisms in oncology, which positions it well to collaborate with pharmaceutical companies seeking advanced cancer therapies or looking to expand their oncology pipelines.

Recent Funding and Growth With a recent Series B funding of 50 million dollars, 858 is experiencing rapid growth and may be open to partnerships, licensing, or strategic alliances to accelerate clinical development and expand its drug portfolio.

Strategic Acquisitions The company's acquisition of Gotham Group enhances its RNA-focused research capabilities, creating opportunities to offer combined or integrated solutions to biotech firms interested in RNA therapeutics or gene regulation therapies.

Biotech Hub Presence Headquartered in San Diego with operations in New York City, 858's geographic positioning provides access to leading biotech ecosystems and scientific talent on both coasts, facilitating collaborations with research institutions and biotech firms.

Pipeline and Licensing Potential Focused on resistant cancers and leveraging cutting-edge science in epigenetics, genomics, and immunity, 858's pipeline presents potential licensing opportunities for companies aiming to diversify or enhance their oncology offerings.